Different Expression Of FoxM1 In Human Benign And Malignant Pleural Effusion

Objective To analyze the forkhead box M1 (FoxMl) expression in benign and malignant pleural effusion by reverse transcription-polymerase chain reaction assay (RT-PCR). To explore the role of FoxM1 in formation and progress in malignant pleural effusion, and whether there is significant difference in expression level of FoxM1 between benign and malignant pleural effusion. To seek a gene marker diagnostically useful to identify benign and malignant pleural effusion in diagnosis and treatment of pleural effusion.Method Collect expression level data of FoxMl in 23 malignant pleural effusion samples (17 adenocarcinoma samples,4 squamous carcinoma samples and 2 small-cell lung carcinoma samples) and 15 benign pleural effusion samples (11 inflammatory pleural effusions,2 transudates,2 tuberculous pleural effusions) by RT-PCR.Results Among all 38 samples, average FoxMl expression level of benign pleural effusions is (235.09±59.99), while malignant pleural effusions (828.77±109.76). Among 23 malignant samples, average FoxMl expression level is (529.27±75.85) in samples without cytological diagnostic evidence, while (1218.12±167.21) in samples with cytological diagnostic evidence. Differences of FoxM1 expression level between benign pleural effusions and malignant ones have statistical significance, either as a whole malignant group, without cytological diagnostic evidence, or with cytological diagnostic evidence. There is an area of 0.881 under the receiver operating characteristic curve, which verifies the accuracy of using FoxM 1 expression level as diagnostic index to identify benign and malignant pleural effusions. According to our study, diagnostic sensitivity and specificity for FoxM1 expression level at 418.1 were 82.6% and 86.7% respectively, while 47.8% and 100% respectively at 768.7.Conclusion FoxMl expression level in malignant pleural effusions is significantly higher than in benign ones. Meanwhile, FoxMl expression level in malignant effusions with cytological diagnostic evidence is higher than in malignant ones without cytological diagnostic evidence. This study provides a new approach in clinical diagnosis, with FoxMl as a specific molecule marker to identify benign and malignant pleural effusions. FoxMl expression level could provide evidence for diagnosis and treatment of malignant pleural effusions and lung cancer.